Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes

Carregando...
Imagem de Miniatura
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Citação
VACCINE, v.32, n.32, p.4104-4110, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Streptococcus pyogenes is responsible for infections as pharyngitis, sepsis, necrotizing fasciitis and streptococcal toxic shock syndrome. The M protein is the major bacterial antigen and consists of both polymorphic N-terminal portion and a conserved region. In the present study, we analyzed the in vitro ability of StreptInCor a C-terminal candidate vaccine against S. pyogenes to induce antibodies to neutralize/opsonize the most common S. pyogenes strains in Sao Paulo by examining the recognition by sera from StreptInCor immunized mice. We also evaluated the presence of cross-reactive antibodies against human heart valve tissue. Anti-StreptInCor antibodies were able to neutralize/opsonize at least 5 strains, showing that immunization with StreptInCor is effective against several S. pyogenes strains and can prevent infection and subsequent sequelae without causing autoimmune reactions.
Palavras-chave
Streptococcus pyogenes, Vaccine, Rheumatic fever, Immunization coverage, Immune response
Referências
  1. Barbosa PJB, 2009, ARQ BRAS CARDIOL, V93, P1
  2. Bessen DE, 2000, J INFECT DIS, V182, P1109, DOI 10.1086/315842
  3. Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0
  4. Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
  5. Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000
  6. Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045
  7. Dale JB, 2013, VACCINE, V31, P1576, DOI 10.1016/j.vaccine.2013.01.019
  8. Goulart C, 2011, VACCINE, V29, P1634, DOI 10.1016/j.vaccine.2010.12.074
  9. Guerino MT, 2011, VACCINE, V29, P8250, DOI 10.1016/j.vaccine.2011.08.113
  10. GUILHERME L, 1995, CIRCULATION, V92, P415
  11. Guilherme L, 2011, UPDATE GLOMERULOPATH
  12. Guilherme L, 2006, CLIN DEV IMMUNOL, V13, P125, DOI 10.1080/17402520600877026
  13. Guilherme L, 2011, J BIOL CHEM, V286, P6989, DOI 10.1074/jbc.M110.132118
  14. Guilherme L, 2011, Ann Pediatr Cardiol, V4, P13, DOI 10.4103/0974-2069.79617
  15. Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024
  16. Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674
  17. Guilherme L, 2011, S PYOGENES INFECT IT, P468
  18. LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
  19. McGregor KF, 2004, J BACTERIOL, V186, P4285, DOI 10.1128/JB.186.13.4285-4294.2004
  20. McMillan DJ, 2013, CLIN MICROBIOL INFEC, V19, pE222, DOI 10.1111/1469-0691.12134
  21. McMillan DJ, 2012, AUTHORS CLIN MICROBI, V5, P222
  22. McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
  23. Narula J, 1999, RHEUMATIC FEVER
  24. Postol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060969
  25. Shulman ST, 2009, CLIN INFECT DIS, V49, P78, DOI 10.1086/599344
  26. Smeesters PR, 2010, TRENDS MICROBIOL, V18, P275, DOI 10.1016/j.tim.2010.02.007
  27. Smeesters PR, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000010
  28. Smeesters PR, 2009, EXPERT REV VACCINES, V8, P1705, DOI [10.1586/erv.09.133, 10.1586/ERV.09.133]
  29. Smeesters PR, 2008, VACCINE, V26, P5835, DOI 10.1016/j.vaccine.2008.08.037
  30. Steer AC, 2013, PEDIATR INFECT DIS J, V32, P180, DOI 10.1097/INF.0b013e318281da11
  31. Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1
  32. Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
  33. Tartof SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-327
  34. TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350